Pharmaceutical Technology
SEPTEMBER 9, 2024
The microbiome, which consists of a vast array of microorganisms inhabiting the human body, has gained considerable attention for its role in health and disease.
AuroBlog - Aurous Healthcare Clinical Trials blog
SEPTEMBER 9, 2024
(Derek Berwin/Getty Images) TThe human papillomavirus (HPV) is responsible for the vast majority of cervical cancer cases, but this isn’t a sexually transmitted infection that just one half of the population needs to worry about.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
SEPTEMBER 9, 2024
PRV-3279 is under clinical development by Sanofi and currently in Phase II for Systemic Lupus Erythematosus.
AuroBlog - Aurous Healthcare Clinical Trials blog
SEPTEMBER 9, 2024
The convergence of gene therapies and clinical research is pushing the boundaries of what’s possible in ophthalmic care, offering hope for more effective treatments and potential cures for a range of vision-threatening conditions.
Pharmaceutical Technology
SEPTEMBER 9, 2024
KOS-1803 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Solid Tumor.
Bio Pharma Dive
SEPTEMBER 9, 2024
A once-daily pill the biotech is developing helped some people with obesity lose more than 5% of their weight in a month, spurring a stock bump and plans to bring the drug into further testing.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Bio Pharma Dive
SEPTEMBER 9, 2024
The startup believes T cell engagers, rather than cell therapies, will prove the “right horse to bet on” in the race to develop new inflammatory disease treatments, its CEO said.
Pharmaceutical Technology
SEPTEMBER 9, 2024
Envafolimab is under clinical development by Alphamab Oncology and currently in Phase II for Merkel Cell Carcinoma.
Bio Pharma Dive
SEPTEMBER 9, 2024
Results from a small study suggest Relay's drug could avoid some of the toxicity associated with existing PI3Ka inhibitors like Novartis' Piqray.
Pharmaceutical Technology
SEPTEMBER 9, 2024
Ifetroban is under clinical development by Cumberland Pharmaceuticals and currently in Phase II for Asthma.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Bio Pharma Dive
SEPTEMBER 9, 2024
The escalating global challenge of Alzheimer's Disease (AD) demands new approaches to detection, diagnosis and treatment.
Pharmaceutical Technology
SEPTEMBER 9, 2024
Venetoclax is under clinical development by AbbVie and currently in Phase III for Mantle Cell Lymphoma.
Pharmaceutical Commerce
SEPTEMBER 9, 2024
In the second part of her interview with Pharma Commerce Editor Nicholas Saraceno, Meghan Mullooly, Archbow Consulting’s Vice President, offers advice to pharma manufacturers for successfully applying digital solutions to their patient support programs.
Pharmaceutical Technology
SEPTEMBER 9, 2024
CC-115 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Solid Tumor.
pharmaphorum
SEPTEMBER 9, 2024
Discover how Chiesi is leading the way in pharmaceutical sustainability by partnering with EcoVadis and implementing innovative practices. Learn how they are making a positive impact on the environment and society.
Pharmaceutical Technology
SEPTEMBER 9, 2024
Alpha-1 proteinase inhibitor (human) second generation is under clinical development by Kamada Pharmaceuticals and currently in Phase II for Alpha-1…
XTalks
SEPTEMBER 9, 2024
The medical device industry continues to thrive in 2024, with advancements in technology shaping the future of healthcare. From cutting-edge surgical robotics to innovative diagnostic tools, the top publicly traded medical device companies are delivering solutions that improve patient care and expand the capabilities of healthcare professionals. Abbott, for instance, leads the industry with breakthroughs in diabetes care and diagnostics, while Stryker’s innovations in orthopedic devices and robo
Pharmaceutical Technology
SEPTEMBER 9, 2024
Avadomide hydrochloride is under clinical development by Bristol-Myers Squibb and currently in Phase I for Glioblastoma Multiforme (GBM).
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
XTalks
SEPTEMBER 9, 2024
Diversity, equity and inclusion (DEI) have become important elements in the landscape of clinical research. It is important for the principles of DEI to be understood for their goals, intended outcomes and applications; otherwise, they may be regarded as mere buzzwords or just another box to tick on organizational mandates. DEI are critical components of building a thriving, fair, all-encompassing, respectful and innovative society.
Pharmaceutical Technology
SEPTEMBER 9, 2024
Alectinib is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Inflammatory Myofibroblastic Tumor (IMT).
pharmaphorum
SEPTEMBER 9, 2024
Summit Therapeutics and Akeso's ivonescimab tops Merck's Keytruda in head-to-head phase 3 trial in first-line NSCLC, reported at WCLC.
Pharmaceutical Technology
SEPTEMBER 9, 2024
PolTREG plans to start a pivotal Phase II/III trial for its Treg cell therapy after it induced clinical remission in type 1 diabetics.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
pharmaphorum
SEPTEMBER 9, 2024
AI biomarker could help identify lung cancer patients most likely to benefit from AstraZeneca and Daiichi Sankyo's TROP2 drug Dato-DXd.
Pharmaceutical Technology
SEPTEMBER 9, 2024
Formosa Pharmaceuticals has announced the first shipment of clobetasol propionate ophthalmic suspension 0.05% (APP13007) to the US.
Pharma Times
SEPTEMBER 9, 2024
Research suggests that LLMs could be used to support trainee doctors, nurses and GPs
Pharmaceutical Technology
SEPTEMBER 9, 2024
Alectinib is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Central Nervous System (CNS) Tumor.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Fierce Pharma
SEPTEMBER 9, 2024
After opting out of Teva’s $4.25 billion national opioid settlement last year, the city of Baltimore has secured its own payout through a settlement deal worth $80 million. | The city scored its own deal after opting not to join in on Teva's $4.25 billion national opioid settlement.
Pharmaceutical Technology
SEPTEMBER 9, 2024
OrsoBio has secured $67m in a Series B financing round to expedite the development of its mitochondrial protonophore portfolio.
Fierce Pharma
SEPTEMBER 9, 2024
When AstraZeneca’s Alexion picked up rare disease specialist Syntimmune in 2018 for $ | A Delaware judge agreed that AstraZeneca's Alexion breached its contract and failed to pay a milestone payment of $130 million tied to the development of a now scrapped autoimmune candidate originally developed by Syntimmune.
Pharmaceutical Technology
SEPTEMBER 9, 2024
Epsilogen has raised £12.5m in a Series B expansion financing round to progress the development of IgE antibodies for cancer.
Advertisement
When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.
Expert insights. Personalized for you.
130 
Let's personalize your content